Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's diseaseAlex E. Roher, Marwan N. Sabbagh, Ian D. Daugs et al.|Alzheimer s & Dementia|2008Cited by 410
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Karl Kieburtz, Shane Rosanbalm et al.|The Lancet Neurology|2023Cited by 128
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical TrialMichael Brownstein, Stephanie Lowenhaupt, Neal G. Simon et al.|Journal of Clinical Medicine|2020Cited by 32
The novel estrogen receptor modulator STX attenuates Amyloid-β neurotoxicity in the 5XFAD mouse model of Alzheimer's diseaseJoseph F. Quinn, Philip F. Copenhaver|Neurobiology of Disease|2022Cited by 14